Medical/Pharmaceuticals

Global Cord Blood Corporation Files Annual Report on Form 20-F

HONG KONG, Aug. 17, 2022 /PRNewswire/ -- Global Cord Blood Corporation (NYSE: CO) ("GCBC" or the "Company"),China's leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing, and stem cell storage services, today announced that the Company filed its Annual ...

2022-08-17 04:16 4784

Kronos Bio and Invivoscribe Partner on Companion Diagnostic for Use with Entospletinib, Kronos Bio's Investigational Compound Being Developed for Patients with AML

Companion diagnostic would be used following potential regulatory approval of entospletinib to screen for NPM1 mutation present in approximately one-third of all patients with AML Entospletinib is currently being studied in the Phase 3 AGILITY registrational study, with data anticipated in seco...

2022-08-17 04:05 4659

WuXi STA Breaks Ground for New Pharmaceutical Manufacturing Facility in Middletown, Delaware

MIDDLETOWN, Del., Aug. 16, 2022 /PRNewswire/ -- WuXi STA, a leading Contract Research, Development, and Manufacturing Organization (CRDMO), is pleased to announce the groundbreaking for its new 190-acre pharmaceutical manufacturing campus inMiddletown, Delaware. First announced in June 2021, this...

2022-08-17 01:47 6009

WeTrade Group Inc. Announces Strategic Cooperation with MobiLab Medical Innovatives Inc., globally launching an unparalleled and one-of-a-kind Monkeypox Virus testing kits with combined insurance coverage products

BEIJING, Aug. 16, 2022 /PRNewswire/ -- WeTrade Group Inc. ("WeTrade" or the "Company") (NASDAQ: WETG), an emerging growth company engaged in the business of providing software-as-a-services (SAAS) and cloud intelligent systems for micro-businesses, today announced the Company has entered into a s...

2022-08-16 20:42 4216

STANDIGM WINS GOLD AND BRONZE STEVIE® AWARDS IN 2022 INTERNATIONAL BUSINESS AWARDS®

Winners to Be Celebrated During Event in London on 15 October SEOUL, South Korea, Aug. 16, 2022 /PRNewswire/ -- Standigm was named the winner of a Gold Stevie® Award in the Pharmaceutical category and a Bronze Stevie® Award in the Computer Software category in The...

2022-08-16 20:30 3753

Vision Loss Rehabilitation Canada brings AI-driven diabetic eye screening to rural and Indigenous communities

Program selects Eyenuk's EyeArt AI system to make vision-saving screening more accessible in remoteOntario communities LOS ANGELES and TORONTO, Aug. 16, 2022 /PRNewswire/ -- Vision Loss Rehabilitation Canada (VLRC), Canada's leading provider of rehabilitation therapy and healthcare services for ...

2022-08-16 20:00 2980

Universe Pharmaceuticals INC Reports Financial Results for The First Six Months of Fiscal Year 2022

JI'AN, China, Aug. 16, 2022 /PRNewswire/ -- Universe Pharmaceuticals INC (the "Company") (Nasdaq: UPC), a pharmaceutical producer and distributor inChina, today announced its unaudited financial results for the first six months of fiscal year 2022 endedMarch 31, 2022. Mr. Gang Lai, Chairman and ...

2022-08-16 20:00 3547

Medison Pharma Announces the Expansion of its Partnership with Albireo to a Multi-Regional Agreement to Commercialize Odevixibat in Canada and Israel

PETACH TIKVAH, Israel, Aug. 16, 2022 /PRNewswire/ -- Medison Pharma ("Medison"), a global pharma company focused on providing access to highly innovative therapies to patients in international markets, announced today the expansion of its partnership withAlbireo ...

2022-08-16 19:30 3078

Profitable growth continues: Exyte with remarkable 6M/2022 results and uplifted year-end outlook

- Order intake rose by almost 50 percent year-on-year, marking a new 6M-high with €4.7 billion - Sales volume increased by almost 50 percent to €3.4 billion - Adjusted EBIT increased by approximately two thirds to €202 million; adjusted EBITDA rose to €222 million, plus over 60 percent - Global...

2022-08-16 16:24 3827

ExoCoBio's First Global Regenerative Aesthetic Exosome Summit

* World First Regenerative Aesthetic Exosome Summit (RAES 2022) * Participation of Global Exosome and Regenerative Aesthetic Authorities * Plan to Grow into a Global Platform for Exosome and Regenerative Aesthetic Industry in the Future SEOUL, South Korea, Aug. 16, 2022 /PRNewswire/ -- ExoCo...

2022-08-16 15:00 9305

Sirnaomics Develops Peptide Docking Vehicle (PDoV(TM)) Designed for an Enhanced GalNAc Delivery Platform for Novel siRNA Therapeutics

A proprietary GalNAc delivery system with enhanced Endosome Escape and Dual-Targeting GAITHERSBURG, Md. and SUZHOU, China, Aug. 16, 2022 /PRNewswire/ -- Sirnaomics Ltd. (the "Company" or "Sirnaomics", stock code: 2257.HK), a leading biopharmaceutical company in discovery and development of RNAi ...

2022-08-16 14:48 4476

J INTS BIO, Oral presentation of Preclinical results of its Novel Oral 4th Generation EGFR TKI 'JIN-A02' at the 2022 World Conference on Lung Cancer in Vienna, Austria (IASLC 2022 WCLC)

SEOUL, South Korea, Aug. 16, 2022 /PRNewswire/ -- J INTS BIO announced that the pre-clinical data of its novel, orally administered 4th generation EGFR TKI 'JIN-A02' was presented on the 8th of August, at the 2022 IASLC World Conference on Lung Cancer held inVienna, Austria, during the official s...

2022-08-16 13:35 2265

ICP DAS - BMP will attend MEDICAL MANUFACTURING ASIA 2022 in Singapore

TAIPEI, Aug. 16, 2022 /PRNewswire/ -- ICP DAS - BMP (Biomedical Polymers), a Taiwanese medical TPU (thermoplastic polyurethane) supplier, will exhibit at MEDICAL MANUFACTURINGASIA 2022, the 5th Manufacturing Processes for Medical Technology Exhibition and Conference, which provides excellent busi...

2022-08-16 10:15 5019

Antengene Announces First Patient Dosed of Small Molecule ATR ATG-018 for the Treatment of Patients with Advanced Solid Tumors and Hematologic Malignancies in Australia

* ATG-018, a global rights asset developed by Antengene's internal R&D team, is anorally-bioavailable, small molecule ataxia telangiectasia and Rad3-associated (ATR) kinase inhibitorthat targets the DNA damage response (DDR) pathways. * The Phase I study will evaluate the safety, pharmacology...

2022-08-16 08:30 3956

Bridge Biotherapeutics Receives FDA Authorization to Proceed with Phase 2 Study of BBT-877

* BBT-877 is intended to explore its treatment efficacy in idiopathic pulmonary fibrosis patients in a Phase II trial expected to start in 2022 SEONGNAM, South Korea, Aug. 15, 2022 /PRNewswire/ -- Bridge Biotherapeutics (KQ288330), a South Korean clinical-stage biotechnology company developing ...

2022-08-16 08:17 2833

Gannex Announces First Subject Dosed in the U.S. Drug-Drug Interaction Study of FXR Agonist ASC42 for Treatment of Primary Biliary Cholangitis

-- Enrollment of the total 12 subjects is expected to be completed in August 2022 -- The DDI study on ASC42 in the U.S. is expected to be completed by the beginning of the fourth quarter 2022 -- This DDI study and ongoing Phase II clinical trial in PBC patients in China will provide more eviden...

2022-08-16 08:10 3918

Everest Medicines Enters into Agreement with Gilead Sciences for Trodelvy in Asia Territories

Everest to receive total considerations of up to $455 million with $280 million in upfront payments Broadens development and access to Trodelvy for patients in Greater China and certain Asia Pacific Markets Strengthens balance sheet and streamlines resources to advance robust pipeline of first-...

2022-08-16 07:15 4878

Lunit Announces Financial Results for the First Half of 2022

* Consolidated revenue in the second quarter of 2022 increased by 190% compared to same prior-year period * Total revenue for H1 2022 amounted to KRW 5.48 billion, or 82.5% of the total revenue of last year SEOUL, South Korea, Aug. 12, 2022 /PRNewswire/ -- Lunit (KRX: 328130.KQ), a global pro...

2022-08-12 21:00 13787

ROKIT Healthcare to Enable Innovation in Treatment of Diabetes Foot and Osteoarthritis Combining AI and 3D Bioprinting on Google Cloud

- Medical platform that converges Cloud, AI, and 3D bioprinting expected to dramatically improve treatment rate and medical access.  SEOUL, South Korea, Aug. 12, 2022 /PRNewswire/ -- ROKIT Healthcare, a company specializing in bio-healthcare, today announced it will provide a hyper-personalized ...

2022-08-12 20:00 16364

Seegene reports H1 2022 financial results

* H1 revenue fell 11% YoY to KRW 579.9 billion, operating profit down 37% to KRW 212.7 billion * Decline due to drop in Q2 sales amid reduced PCR testing volume * Sales of non-COVID products and PCR instruments increased in H1; Company launches STARlet-AIOS to strengthen sales foundation *...

2022-08-12 19:00 15760
1 ... 531532533534535536537 ... 644